Morphine-mediated release of miR-138 in astrocyte-derived extracellular vesicles promotes microglial activation

Ke Liao1, Fang Niu1, Guoku Hu1

  • 1Department of Pharmacology and Experimental Neuroscience University of Nebraska Medical Center Omaha Nebraska USA.

Insights

Morphine exposure triggers the release of miR-138 within extracellular vesicles (EVs), activating microglia via toll-like receptor 7 (TLR7). This mechanism drives neuroinflammation in opioid abuse, suggesting EV-based anti-miRNA therapies.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Opioids are crucial for pain management but associated with increased overdose deaths.
  • Opioid abuse leads to neuroinflammation, though underlying mechanisms are not fully understood.
  • MicroRNAs (miRNAs) are key regulators of gene expression and intercellular communication.

Purpose of the Study:

  • To elucidate the mechanisms by which morphine induces neuroinflammation.
  • To investigate the role of microRNAs and extracellular vesicles in morphine-induced neuroinflammation.

Main Methods:

  • Primary human astrocytes were exposed to morphine.
  • Extracellular vesicles (EVs) containing miRNAs were isolated from astrocyte-conditioned media.
  • Microglia activation was assessed following EV uptake, with specific attention to toll-like receptor 7 (TLR7) interactions.
  • In vivo studies utilized wildtype and TLR7 knockout mice.

Main Results:

  • Morphine induced the release of miR-138 within EVs from astrocytes.
  • These EVs were taken up by microglia, leading to their activation.
  • Microglial activation was dependent on the binding of miR-138's GUUGUGU motif to TLR7.
  • Morphine administration increased microglial activation in wildtype mice but not in TLR7 knockout mice.

Conclusions:

  • Morphine-induced neuroinflammation involves miR-138 packaged in EVs, which activate microglia through TLR7.
  • This pathway is critical for understanding opioid neurotoxicity.
  • EV-loaded anti-miRNAs represent a potential therapeutic strategy for opioid-associated neuroinflammation.